These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35602377)

  • 41. Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside.
    Augustine A; Winstanley CA; Krishnan V
    Front Neurosci; 2021; 15():654238. PubMed ID: 33790738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia.
    Oh YS; Kim JS; Lee PH
    J Mov Disord; 2015 May; 8(2):98-102. PubMed ID: 26090082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Othello syndrome in patients with Parkinson's disease.
    Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
    Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders.
    Raja M; Bentivoglio AR
    Curr Drug Saf; 2012 Feb; 7(1):63-75. PubMed ID: 22663960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of behavioral and psychiatric problems in Parkinson's disease.
    Rabinstein AA; Shulman LM
    Parkinsonism Relat Disord; 2000 Nov; 7(1):41-50. PubMed ID: 11008195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impulse control and related behaviors in Parkinson's disease with dementia.
    Martinez-Martin P; Wan YM; Ray Chaudhuri K; Schrag AE; Weintraub D
    Eur J Neurol; 2020 Jun; 27(6):944-950. PubMed ID: 32048392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
    Ramirez-Zamora A; Gee L; Boyd J; Biller J
    Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of behavioural symptoms and dementia in Parkinson's disease.
    Hanagasi HA; Emre M
    Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.
    Mueller C; Rajkumar AP; Wan YM; Velayudhan L; Ffytche D; Chaudhuri KR; Aarsland D
    CNS Drugs; 2018 Jul; 32(7):621-635. PubMed ID: 30027401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence, etiology, and treatment of depression in Parkinson's disease.
    McDonald WM; Richard IH; DeLong MR
    Biol Psychiatry; 2003 Aug; 54(3):363-75. PubMed ID: 12893111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impulse-control disorders in Parkinson's disease.
    Ferrara JM; Stacy M
    CNS Spectr; 2008 Aug; 13(8):690-8. PubMed ID: 18704024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug treatments for the neuropsychiatric complications of Parkinson's disease.
    Connolly BS; Fox SH
    Expert Rev Neurother; 2012 Dec; 12(12):1439-49. PubMed ID: 23237351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of impulse control disorders in Parkinson's disease.
    Zhang S; Dissanayaka NN; Dawson A; O'Sullivan JD; Mosley P; Hall W; Carter A
    Int Psychogeriatr; 2016 Oct; 28(10):1597-614. PubMed ID: 27373317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The syndromal validity and nosological position of apathy in Parkinson's disease.
    Starkstein SE; Merello M; Jorge R; Brockman S; Bruce D; Power B
    Mov Disord; 2009 Jun; 24(8):1211-6. PubMed ID: 19412942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Single-institution Study on Predictors of Short-term Progression from Mild Cognitive Impairment in Parkinson's Disease to Parkinson's Disease with Dementia.
    Tajiri Y; Wada-Isoe K; Tanaka K; Adachi T; Hanajima R; Nakashima K
    Yonago Acta Med; 2020 Feb; 63(1):28-33. PubMed ID: 32158330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of bilateral stimulation of the subthalamic nucleus in Parkinson's disease with and without REM sleep behaviour disorder.
    Bargiotas P; Debove I; Bargiotas I; Lachenmayer ML; Ntafouli M; Vayatis N; Schüpbach MW; Krack P; Bassetti CL
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1310-1316. PubMed ID: 31422368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palliative care in Parkinson's disease: role of cognitive behavior therapy.
    Mallick S
    Indian J Palliat Care; 2009 Jan; 15(1):51-6. PubMed ID: 20606856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.